A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

标题
A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 15_suppl, Pages 3004-3004
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2017-02-24
DOI
10.1200/jco.2010.28.15_suppl.3004

向作者/读者发起求助以获取更多资源

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More